Roivant Sciences (ROIV) News Today → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free ROIV Stock Alerts $10.36 -0.03 (-0.29%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 6:36 AM | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) Receives Buy Rating from HC WainwrightJune 1 at 2:16 AM | americanbankingnews.comQ1 2025 EPS Estimates for Roivant Sciences Ltd. Cut by Leerink Partnrs (NASDAQ:ROIV)May 31 at 8:41 AM | marketbeat.comLeerink Partnrs Equities Analysts Cut Earnings Estimates for Roivant Sciences Ltd. (NASDAQ:ROIV)Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) - Investment analysts at Leerink Partnrs cut their Q1 2025 earnings estimates for Roivant Sciences in a research report issued on Wednesday, May 29th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings per share ofMay 31 at 8:25 AM | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Roivant Sciences (NASDAQ:ROIV)HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Friday.May 30 at 1:22 PM | investorplace.comROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024May 30 at 11:53 AM | marketbeat.comDecheng Capital LLC Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV)Decheng Capital LLC acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,279,700 shares of the company's stock, valued at approximately $14,371,May 30 at 7:00 AM | globenewswire.comRoivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business UpdateMay 29, 2024 | marketbeat.comMonashee Investment Management LLC Decreases Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)Monashee Investment Management LLC cut its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 36.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 350,000 shares of the company's stock after selling 200,00May 29, 2024 | markets.businessinsider.comRoivant Sciences is about to announce its earnings — here's what Wall Street expectsMay 29, 2024 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Shares Gap Up to $10.83Roivant Sciences (NASDAQ:ROIV) Shares Gap Up to $10.83May 29, 2024 | uk.news.yahoo.comRamaswamy Urges BuzzFeed to Cut Costs, Air Conservative VoicesMay 29, 2024 | msn.comVivek Ramaswamy pressures BuzzFeed to hire Tucker Carlson and shift to the RightMay 25, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 99,148 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)Charles Schwab Investment Management Inc. lifted its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 5.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,023,027 shares of the company'sMay 23, 2024 | americanbankingnews.comRoivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 23, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of "Moderate Buy" by AnalystsRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has earned an average rating of "Moderate Buy" from the ten research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to thMay 23, 2024 | americanbankingnews.comRoivant Sciences (ROIV) Scheduled to Post Earnings on ThursdayMay 22, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. cut its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 91.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,823 shares of the company's stock after selling 78May 16, 2024 | globenewswire.comRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024May 15, 2024 | marketbeat.comFirst Turn Management LLC Takes $15.31 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)First Turn Management LLC acquired a new position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,363,504 shares of the company'sMay 14, 2024 | marketbeat.comPertento Partners LLP Acquires Shares of 879,214 Roivant Sciences Ltd. (NASDAQ:ROIV)Pertento Partners LLP bought a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 879,214 shares of the company's stock, valued aMay 7, 2024 | investorplace.comBiotech Breakthroughs: 7 Stocks Driving the Next Wave in HealthcareMay 1, 2024 | investorplace.com3 Healthcare Stocks With the Potential to Triple Your Investment by 2026April 28, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Short Interest UpdateRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 45,130,000 shares, an increase of 45.9% from the March 31st total of 30,930,000 shares. Approximately 8.2% of the company's stock are sold short. Based on an average trading volume of 7,280,000 shares, the days-to-cover ratio is currently 6.2 days.April 26, 2024 | marketbeat.comabrdn plc Makes New $12.66 Million Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)abrdn plc purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,126,987 shares of the company's stock, valued aApril 25, 2024 | businesswire.comRoivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary SarcoidosisApril 24, 2024 | seekingalpha.comRoivant Sciences: Cashing In On Vants And VenturesApril 22, 2024 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Monday.April 14, 2024 | markets.businessinsider.comSunrun (RUN) Gets a Buy from RBC CapitalApril 8, 2024 | marketbeat.comVanguard Group Inc. Has $65.44 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)Vanguard Group Inc. increased its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 159.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,602,566 shares of the company's stock after purchaApril 5, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Roivant Sciences Ltd.'s Q1 2025 Earnings (NASDAQ:ROIV)Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) - HC Wainwright lowered their Q1 2025 earnings per share estimates for Roivant Sciences in a research note issued on Wednesday, April 3rd. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.25) per share for the quarter, downApril 4, 2024 | msn.comRoivant's anti-inflammatory drug shows promise in mid-stage studyApril 3, 2024 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Sees Large Volume Increase Following Analyst UpgradeRoivant Sciences (NASDAQ:ROIV) Sees Large Volume Increase After Analyst UpgradeApril 3, 2024 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Given New $18.00 Price Target at The Goldman Sachs GroupThe Goldman Sachs Group increased their price objective on shares of Roivant Sciences from $16.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday.April 3, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Given Average Recommendation of "Moderate Buy" by AnalystsRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and nine have given a buy recommendationApril 2, 2024 | marketbeat.comRoivant Sciences Sees Unusually High Options Volume (NASDAQ:ROIV)Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders purchased 11,070 call options on the stock. This represents an increase of 209% compared to the typical daily volume of 3,588 call options.April 2, 2024 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Shares Gap Up to $10.43Roivant Sciences (NASDAQ:ROIV) Shares Gap Up to $10.43April 2, 2024 | msn.comRoivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease StudyApril 2, 2024 | reuters.comRoivant's anti-inflammatory drug succeeds in mid-stage studyApril 2, 2024 | globenewswire.comRoivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 MillionApril 1, 2024 | msn.comCompare with CoinDesk Market Index (CDICMI)March 29, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $11.94 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)Assenagon Asset Management S.A. lifted its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 195.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,063,392 shares of the company's stock after acquiMarch 28, 2024 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Shares Down 4% Roivant Sciences (NASDAQ:ROIV) Trading Down 4%March 27, 2024 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Shares Gap Up to $10.08Roivant Sciences (NASDAQ:ROIV) Shares Gap Up to $10.08March 26, 2024 | msn.comViking Therapeutics gains on early data for oral weight loss therapyMarch 26, 2024 | msn.com'Some people have principles': Internet divided as Vivek Ramaswamy predicts NY ruling against Trump could energize key voter groupMarch 25, 2024 | marketbeat.comTruist Financial Reaffirms "Buy" Rating for Roivant Sciences (NASDAQ:ROIV)Truist Financial restated a "buy" rating and set a $23.00 target price on shares of Roivant Sciences in a research report on Monday.March 21, 2024 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Shares Gap Up to $10.01Roivant Sciences (NASDAQ:ROIV) Shares Gap Up to $10.01March 17, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by Citigroup Inc.Citigroup Inc. increased its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 45.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 326,431 shares of the company's stock after purcMarch 16, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Wellington Management Group LLPWellington Management Group LLP reduced its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 2.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,842,976 shares of theMarch 15, 2024 | marketbeat.comInvestors Purchase Large Volume of Roivant Sciences Put Options (NASDAQ:ROIV)Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) was the recipient of some unusual options trading activity on Friday. Stock traders bought 30,219 put options on the stock. This is an increase of approximately 883% compared to the typical daily volume of 3,073 put options. Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address The Worst is Yet to Come… (Ad)Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly. Click here to stream this controversial exposé now. ROIV Media Mentions By Week ROIV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ROIV News Sentiment▼0.130.76▲Average Medical News Sentiment ROIV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ROIV Articles This Week▼176▲ROIV Articles Average Week Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALNY News Today TEVA News Today GMAB News Today RPRX News Today BGNE News Today BMRN News Today VTRS News Today UTHR News Today RDY News Today SRPT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ROIV) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
